Início › Câncer de Rim (Carcinoma de Células Renais) › Oregon › Portland
Ensaios clínicos de Câncer de Rim (Carcinoma de Células Renais) em Portland, OR
11 estudos para Câncer de Rim (Carcinoma de Células Renais) estão buscando participantes em locais em Portland e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · a 12 mi de distância
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecrutandoFase 1
- Exelixis Clinical Site #51, Portland
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecrutandoFase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RecrutandoFase 1/2
- Northwest Cancer Specialists, P.C., Portland
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
RecrutandoFase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
- e mais 1
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
RecrutandoFase 1/2
- Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
A Study of MGC026 in Participants With Advanced Solid Tumors
RecrutandoFase 1
- Providence Cancer Institute, Portland
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
RecrutandoFase 1/2
- Oregon Health & Science University (3485 S. Bond), Portland
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
RecrutandoFase 4
- OHSU Knight Cancer Institute, Portland
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RecrutandoFase 1
- Oregon Health & Science University, Portland
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
RecrutandoFase 3
- Kaiser Permanente Northwest, Portland
- Oregon Health and Science University, Portland
Ensaios de Câncer de Rim (Carcinoma de Células Renais) em outras cidades
- Houston, TX35 estudos
- New York City, NY27 estudos
- Dallas, TX23 estudos
- Nashville, TN23 estudos
- St. Louis, MO23 estudos
- Los Angeles, CA20 estudos
- Boston, MA16 estudos
- Baldwin Park, CA16 estudos
- Pittsburgh, PA15 estudos
- Philadelphia, PA15 estudos
- Queens, NY15 estudos
- Cleveland, OH14 estudos
Outros estudos em Portland
- Câncer de Pulmão de Não Pequenas Células46 estudos
- Câncer (todos os tipos)34 estudos
- Câncer de Mama33 estudos
- Câncer de Próstata33 estudos
- Câncer Metastático29 estudos
- Câncer Colorretal28 estudos
- Câncer de Ovário27 estudos
- Câncer de Pulmão26 estudos
- Leucemia Mieloide Aguda25 estudos
- Câncer Endometrial24 estudos
- Carcinoma de Células Escamosas de Cabeça e Pescoço19 estudos
- Câncer de Pâncreas19 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.